Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01734512 · ClinicalTrials.gov registry record · Phase 2
PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children
A Phase 2 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 2
- Development phase
- 65
- Enrollment target
NCT01734512: Completed Phase 2 study, sponsored by University of California, San Francisco.
NCT01734512 is a Phase 2 study that has completed, run by University of California, San Francisco. The registered enrollment target is 65 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01734512, a Phase 2 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 65 participants
- Enrollment target
Study Summary
This is an open label study of everolimus in children with recurrent or progressive low-grade glioma.
Primary Outcome
Response was be determined by bi-dimensional diameters. RECIST criteria will be collected and used for secondary evaluation. Patients will have brain MRI scans with and without gadolinium performed prior to therapy, after every second course in the first year, after every third course in the second year, and at the End of Study visit (if not done within prior 3 months). Spine MRIs should be performed prior to therapy and at the same time points as standard brain MRIs if clinically indicated.
Interventions
- DRUG Everolimus
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 65 participants |
| Start Date | 2012-12-13 |
| Est. Completion | 2024-07-31 |
| Phase | Phase 2 |
What the finished NCT01734512 record still lists
NCT01734512 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 65 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% lower).
The record links to 0 conditions, and to 1 intervention - of which Everolimus is the first listed.
NCT01734512 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01734512 about?
NCT01734512 is a clinical study titled "PNOC 001: Phase II Study of Everolimus for Recurrent or Progressive Low-grade Gliomas in Children". This is an open label study of everolimus in children with recurrent or progressive low-grade glioma.
What is the current status of trial NCT01734512?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 65 participants. The study started on 2012-12-13. Estimated completion is 2024-07-31.
What interventions are being tested in trial NCT01734512?
The interventions under investigation include: Everolimus (DRUG).
Who is sponsoring clinical trial NCT01734512?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01734512's enrollment target sits among peer trials
65 987th of 2000 higher than 1,005 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03366116 · 65 participants · Phase 1
5-aza-4'-Thio-2'-Deoxycytidine (Aza-TdC) in People With Advanced Solid Tumors
- NCT03603730 · 65 participants · NA
Vagal Nerve Stimulation for Functional Dyspepsia and Gastroparesis
- NCT03796559 · 65 participants · NA
Magseed Enabled Long-Term Localization of Axillary Lymph Nodes
- NCT03993106 · 65 participants · Phase 2
A Study of sEphB4-HSA in Kaposi Sarcoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI